Skip to main content

Table 3 Best overall response (per RECIST) for patients treated in Phase 2 with IL-21 (30 mcg/kg) plus sorafenib (starting at 400 mg twice daily)

From: Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study

RECIST response Investigator assessment (N = 33) Independent review (N = 33)
Complete response 0 0
Partial response 6 (18%) 7 (21%)
Stable disease 22 (67%) 20 (61%)
Progressive disease 4 (12%) 4 (12%)
Unavailable* 1 (3%) 2 (6%)
  1. *Includes 1 subject who discontinued for toxicity prior to disease reassessment by both investigator and independent review and 1 subject with progressive disease on imaging not sent for independent review. All objective responses were confirmed on a subsequent imaging study.